Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-17-006814
Filing Date
2017-02-01
Accepted
2017-02-01 17:21:56
Documents
1
Period of Report
2017-01-27

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 4986
  Complete submission text file 0001209191-17-006814.txt   6537
Mailing Address 2601 FOURTH AVENUE SUITE 500 SEATTLE WA 98121
Business Address 2601 FOURTH AVENUE SUITE 500 SEATTLE WA 98121 (206) 801-2100
Cascadian Therapeutics, Inc. (Issuer) CIK: 0001412067 (see all company filings)

EIN.: 260868560 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 8731 Services-Commercial Physical & Biological Research

Mailing Address 2855 SAND HILL ROAD MENLO PARK CA 94025
Business Address
Sakoda Jon (Reporting) CIK: 0001589961 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-33882 | Film No.: 17565873